Pre-order Enquiry
Request Free Sample
Global Antibody Fragments Market Insights, Forecast to 2028
SKU ID : QYR-20244731 | Publishing Date : 17-Feb-2022 | No. of pages : 105
Market Analysis and Insights: Global Antibody Fragments Market
Due to the COVID-19 pandemic, the global Antibody Fragments market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, F(ab) Fragment accounting for % of the Antibody Fragments global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Cancer segment is altered to an % CAGR throughout this forecast period.
China Antibody Fragments market size is valued at US$ million in 2021, while the US and Europe Antibody Fragments are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antibody Fragments landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Antibody Fragments include Novartis, F. Hoffmann-La Roche, Johnson & Johnson, Amgen, Bristol-Myers Squibb, AbbVie, Takeda Pharmaceutical, Sanofi and Biogen and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Antibody Fragments Scope and Segment
Antibody Fragments market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Antibody Fragments market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
F(ab) Fragment
F(ab’)2 Fragment
Segment by Application
Cancer
Immunodeficiencies
Other
By Company
Novartis
F. Hoffmann-La Roche
Johnson & Johnson
Amgen
Bristol-Myers Squibb
AbbVie
Takeda Pharmaceutical
Sanofi
Biogen
Eli Lilly
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Due to the COVID-19 pandemic, the global Antibody Fragments market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, F(ab) Fragment accounting for % of the Antibody Fragments global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Cancer segment is altered to an % CAGR throughout this forecast period.
China Antibody Fragments market size is valued at US$ million in 2021, while the US and Europe Antibody Fragments are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antibody Fragments landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Antibody Fragments include Novartis, F. Hoffmann-La Roche, Johnson & Johnson, Amgen, Bristol-Myers Squibb, AbbVie, Takeda Pharmaceutical, Sanofi and Biogen and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Antibody Fragments Scope and Segment
Antibody Fragments market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Antibody Fragments market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
F(ab) Fragment
F(ab’)2 Fragment
Segment by Application
Cancer
Immunodeficiencies
Other
By Company
Novartis
F. Hoffmann-La Roche
Johnson & Johnson
Amgen
Bristol-Myers Squibb
AbbVie
Takeda Pharmaceutical
Sanofi
Biogen
Eli Lilly
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
